First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
Go or no go? Bristol's first-in-class hopes
April should mark the approval of some of the biggest drugs of 2022, including Alnylam's vutrisiran, while TG will hope to be spared pain at the PI3K adcom.
Another strike for biotech: China
Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.
Ash 2021 – Forma takes on a second Agios drug
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
Five Prime looks to turn a corner
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
Triple meeting – the point of turning to TPX-0022
The first look at Turning Point’s TPX-0022 shows signs of activity beyond cMet inhibitors’ proven use in lung cancer.
